Financial Report: Merck 1Q

Merck

1Q Revenues: $9.4 billion (-8%)

1Q Earnings: $953 million (-44%)

Comments: Pharmaceutical sales were $8.3 billion, down 2% in the quarter. JANUVIA/JANUMET sales were $1.4 billion, up 4%. ZETIA/VYTORIN sales were down 9% to $887 million. REMICADE sales were down 17% to $501 million. ISENTRESS sales were $385 million, down 1%. GARDASIL / GARDASIL 9 sales were down 6% to $359 million. PROQUAD, M-M-R II and VARIVAX sales were up 24% to $348 million. Animal Health revenues were up 2% to $829 million. Results include a 5% negative impact from foreign exchange and a 9% unfavorable impact from the divestiture of the Consumer Care business and select products, partially offset by the acquisition of Cubist Pharmaceuticals.